Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

Background: Because sunitinib can induce extensive necrosis in metastatic renal cell cancer (mRCC), we examined whether criteria defined by Choi might be valuable to predict early sunitinib efficacy. Methods: Computed tomography was used for measurement of tumour lesions in mm and lesion attenuation...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2010-03, Vol.102 (5), p.803-809
Main Authors: van der Veldt, A A M, Meijerink, M R, van den Eertwegh, A J M, Haanen, J B A G, Boven, E
Format: Article
Language:English
Subjects:
631/154/436/108
692/699/67/1059
692/699/67/589/1588/1351
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Cancer Research
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - secondary
Clinical outcomes
Clinical Study
Drug Resistance
Epidemiology
Female
Humans
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Kidneys
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Male
Medical sciences
Middle Aged
Molecular Medicine
Neoplasm Staging
Nephrology. Urinary tract diseases
Oncology
Prognosis
Pyrroles - therapeutic use
Survival Rate
Tomography, X-Ray Computed
Treatment Outcome
Tumors
Tumors of the urinary system
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Because sunitinib can induce extensive necrosis in metastatic renal cell cancer (mRCC), we examined whether criteria defined by Choi might be valuable to predict early sunitinib efficacy. Methods: Computed tomography was used for measurement of tumour lesions in mm and lesion attenuation in Hounsfield units (HUs). According to Choi criteria partial response (PR) was defined as ⩾10% decrease in size or ⩾15% decrease in attenuation. Results: A total of 55 mRCC patients treated with sunitinib were included. At first evaluation, according to the Response Evaluation Criteria in Solid Tumours (RECIST) 7 patients had PR, 38 stable disease (SD), and 10 progressive disease (PD), whereas according to Choi criteria 36 patients had PR, 6 SD and 13 PD. Median tumour attenuation decreased from 66 to 47 HUs ( P ⩽0.001). In patients with PR, Choi criteria had a significantly better predictive value for progression-free survival and overall survival (both P s
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605567